MedPage Today September 10, 2025
The answer matters both clinically and financially, but clarity may not come soon
New FDA approval language for COVID-19 vaccines is sowing confusion about which conditions put people at greater risk for severe disease and who can avoid the inconvenience and cost of off-label immunization.
That confusion may deepen as the rift widens between what federal vaccine authorities say and what medical organizations recommend.
Last month, the FDA approved the 2025-2026 COVID vaccines for all adults 65 and older, but limited their use in younger people to those with at least one condition that puts them at high risk for severe disease.
The agency’s restrictions are part of a growing trend away from broader support for COVID vaccination under the...
Today's Sponsors
Today's Sponsor